SCHEMBL5405907

SCHEMBL5405907

CCOc1ccc(CCN(CCC(=O)O)C(=O)c2ccccc2-c2ccccc2C(=O)NCc2cc(F)cc(F)c2)cc1OC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
APP P05067 1/20 0.44
PPARA Q07869 3/20 0.43
PPARG P37231 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
ALDH1A1 P00352 1/20 0.42
HPGD P15428 1/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
HCRTR1 O43613 1/20 0.42
HCRTR2 O43614 1/20 0.42
APEX1 P27695 1/20 0.41
KDM4E B2RXH2 2/20 0.40
RXFP1 Q9HBX9 1/20 0.40
PDE10A Q9Y233 1/20 0.40
TP53 P04637 2/20 0.40
MAPT P10636 1/20 0.40
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5409385 0.97 MEN1 (0.46) LMNASMN1; SMN2APPPPARAPPARG
SCHEMBL4928591 0.94 LMNA (0.47) LMNASMN1; SMN2APPPPARAPPARG
SCHEMBL5398027 0.94 APEX1 (0.46) LMNASMN1; SMN2PPARAPPARGMEN1
SCHEMBL5394236 0.94 MEN1 (0.51) LMNASMN1; SMN2APPPPARAPPARG
SCHEMBL5403428 0.93 APP (0.49) LMNASMN1; SMN2APPPPARAPPARG
SCHEMBL5401067 0.91 LMNA (0.47) LMNASMN1; SMN2PPARAPPARGMEN1
SCHEMBL5392923 0.91 MEN1 (0.55) LMNASMN1; SMN2APPPPARAPPARG
SCHEMBL4931284 0.90 PPARA (0.46) LMNAAPPPPARAPPARGALDH1A1
SCHEMBL4921807 0.90 LMNA (0.46) LMNASMN1; SMN2APPPPARAPPARG
SCHEMBL5405822 0.90 SMN1; SMN2 (0.46) LMNASMN1; SMN2APPPPARAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285680-B2 β-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-10-23 US disclosed
US-20050256160-A1 Beta-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2005-11-17 US disclosed
EP-1533294-A1 BETA-ALANINE DERIVATIVE AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256160-A1 Beta-alanine derivatives and the use thereof TGFB1, PML, APOB LMNA 308/4885SMN1; SMN2 57/4885APP 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.